Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Ovarian Neoplasms 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

fludarabine phosphate 43Whole-Body Irradiation 36Mycophenolic Acid 36Peripheral Blood Stem Cell Transplantation 31Cyclophosphamide 31Tacrolimus 28Busulfan 22Antilymphocyte Serum 21Cyclosporine 19fludarabine 17ruxolitinib 16Melphalan 16Methotrexate 15Cytarabine 12thymoglobulin 9Sirolimus 9Etoposide 9Granulocyte Colony-Stimulating Factor 8Filgrastim 8Cyclosporins 8Radiotherapy 7Cord Blood Stem Cell Transplantation 7Rituximab 6Alemtuzumab 6merphos 5Stem Cell Transplantation 5Flow Cytometry 5Azacitidine 5sargramostim 4ponatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myeloproliferative Disorders × guadecitabine × Clear all
NCT03075826 2022-05-05

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Weill Medical College of Cornell University

Phase 2 Completed
22 enrolled 8 charts
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡